Global Thyroid Cancer Drugs Market Share Report 2024, Forecast To 2033
22 Jan, 2024
The thyroid cancer drugs market has experienced rapid growth, increasing from $1.01 billion in 2023 to $1.16 billion in 2024, marking a 15.3% CAGR. Historical drivers include the increasing incidence of thyroid cancer, advances in medical research, a favorable regulatory environment, and growing healthcare expenditure. Forecasts suggest continued rapid growth, projecting a size of $1.96 billion in 2028, with a 14.1% CAGR. Growth is attributed to increasing prevalence, aging population, advancements in precision medicine, healthcare infrastructure development, and rising awareness and early detection. Key trends involve personalized medicine, targeted therapies and immunotherapies, clinical trials, drug pipeline, combination therapies, biomarker-driven treatments, and telemedicine and remote monitoring.
Global Thyroid Cancer Drugs Market Key Driver
The thyroid cancer drugs market sees growth due to increasing incidences, especially in women. In 2022, the American Cancer Society estimated around 43,800 new cases of thyroid cancer in the United States, with 31,940 cases in women. Rising incidences, particularly in women, fuel the growth of the thyroid cancer drugs market.
Get A Free Sample Of The Global Thyroid Cancer Drugs Market ReportGlobal Thyroid Cancer Drugs Market Segments
The thyroid cancer drugs market covered in this report is segmented –
1) By Drug Type: Ipilimumab, Cabozantinib-S-Malate, Caprelsa (Vandetanib), Doxorubicin Hydrochloride, Lenvatinib Mesylate, Nivolumab, Vandetanib, Other Drug Types
2) By Type: Radioiodine Ablation, Thyroid Stimulating Hormone (THS) Suppression, Chemotherapy, Targeted Multikinase Therapy, Other Types
3) By End Users: Hospitals, Oncology Clinics, Research Organizations, Other End-Users
By Geography: The regions covered in the thyroid cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions
North America was the largest region in the thyroid cancer drugs market in 20232. Middle East is expected to be the fastest-growing region in the thyroid cancer drugs market during the forecast period. The regions covered in the thyroid cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Thyroid Cancer Drugs Industry Players
Mylan Pharmaceuticals Inc., Alara Pharmaceutical Corporation, Baxter International Inc., Abbott Laboratories, APP Pharmaceuticals LLC, AstraZeneca PLC, GlaxoSmithKline plc, Exelixis Inc., Novartis AG, Pfizer Inc., Biovista Inc., Vascular Biogenics Ltd., Azaya Therapeutics Inc., Bionomics Limited, Bayer AG, Eisai Co. Ltd., Bio-Path Holdings Inc., Takeda Pharmaceutical Company Limited, AbbVie Inc., Bristol-Myers Squibb Company, Celgene Corporation (a subsidiary of Bristol-Myers Squibb Company), Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Hikma Pharmaceuticals PLC, Ipsen Biopharmaceuticals Inc., Johnson & Johnson, Kyowa Kirin Co. Ltd., Merck & Co. Inc., Sanofi S.A., Amgen Inc., Astellas Pharma Inc., Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Gilead Sciences Inc., Grifols S.A., Jazz Pharmaceuticals plc, Mallinckrodt Pharmaceuticals (a subsidiary of Specialty Generics Holdings), Medtronic plc, Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co. Ltd.
Get The Full Global Thyroid Cancer Drugs Market Report
Thyroid Cancer Drugs Market Overview
The thyroid cancer drugs refer to drugs that are used to treat thyroid cancer by blocking several different kinase proteins. These medications function primarily in two ways. First, they aid in preventing tumours from growing new blood vessels, which they require to do so. They target a few of the proteins that cancer cells often produce to aid in their growth. The thyroid tissue is made up of follicular cells and parafollicular cells in which cancer develops.
Thyroid Cancer Drugs Global Market Report 2023 provides data on the global thyroid cancer drugs market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The thyroid cancer drugs market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.